Diagnoly

Diagnoly is transforming prenatal care by bringing real-time artificial intelligence to fetal ultrasound. Founded in Lyon in 2021, the company has developed a software co-pilot that assists sonographers during fetal scans by analyzing image streams in real time to detect anomalies that might otherwise go unnoticed.

The first version of Diagnoly’s software focuses on congenital heart defects and has already received FDA approval (October 2024). It boasts a detection rate above 90%, significantly outperforming the 50–70% range observed in manual clinical practice. Its early adopters—spread across Europe and the U.S.—have all converted from test users to paying clients, a testament to the software’s clinical value.

Diagnoly raised €3M in 2025, co-led by Newfund HEKA and XAnge. The funding will accelerate its expansion to brain and full-organ fetal diagnostics, regulatory approvals in Europe and the U.S., deployment across 500 practitioners, with a strong focus on U.S. adoption.